IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, announced that CEO and co-founder William Ho will present at NobleCon20 on December 3, 2024, at 10:30 am ET. The presentation will be available through a high-definition video webcast on the company's investor relations website, Noble Capital Markets' Conference website, and Channelchek platform. The webcast recording will remain accessible for 90 days after the event on all three platforms.
IN8bio (Nasdaq: INAB), un'azienda biofarmaceutica in fase clinica che si concentra sulle terapie con cellule T gamma-delta, ha annunciato che il CEO e co-fondatore William Ho presenterà al NobleCon20 il 3 dicembre 2024, alle 10:30 ET. La presentazione sarà disponibile tramite un webcast video in alta definizione sul sito web delle relazioni con gli investitori dell'azienda, sul sito della conferenza di Noble Capital Markets e sulla piattaforma Channelchek. La registrazione del webcast rimarrà accessibile per 90 giorni dopo l'evento su tutte e tre le piattaforme.
IN8bio (Nasdaq: INAB), una empresa biofarmacéutica en fase clínica centrada en terapias con células T gamma-delta, anunció que el CEO y cofundador William Ho presentará en NobleCon20 el 3 de diciembre de 2024, a las 10:30 a. m. ET. La presentación estará disponible a través de un webcast en video de alta definición en el sitio web de relaciones con inversores de la empresa, en el sitio web de la conferencia de Noble Capital Markets y en la plataforma Channelchek. La grabación del webcast permanecerá accesible durante 90 días después del evento en las tres plataformas.
IN8bio (Nasdaq: INAB)는 감마 델타 T 세포 치료에 중점을 둔 임상 단계의 생명공학 회사로, CEO이자 공동 창립자인 윌리엄 호가 2024년 12월 3일 오전 10시 30분 ET에 NobleCon20에서 발표할 것이라고 발표했습니다. 발표는 회사의 투자자 관계 웹사이트, Noble Capital Markets 컨퍼런스 웹사이트 및 Channelchek 플랫폼을 통해 고화질 비디오 웹캐스트로 제공됩니다. 웹캐스트 녹화는 이벤트 후 90일 동안 세 플랫폼 모두에서 접근 가능하게 유지됩니다.
IN8bio (Nasdaq: INAB), une entreprise biopharmaceutique en phase clinique axée sur les thérapies par cellules T gamma-delta, a annoncé que le PDG et co-fondateur William Ho présentera au NobleCon20 le 3 décembre 2024 à 10h30 ET. La présentation sera disponible via un webcast vidéo haute définition sur le site des relations avec les investisseurs de l'entreprise, le site de la conférence de Noble Capital Markets et la plateforme Channelchek. L'enregistrement du webcast restera accessible pendant 90 jours après l'événement sur les trois plateformes.
IN8bio (Nasdaq: INAB), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Gamma-Delta-T-Zelltherapien spezialisiert hat, gab bekannt, dass CEO und Mitbegründer William Ho am 3. Dezember 2024 um 10:30 Uhr ET auf der NobleCon20 präsentieren wird. Die Präsentation wird über einen hochauflösenden Video-Webcast auf der Investor-Relations-Website des Unternehmens, der Website der Noble Capital Markets-Konferenz und der Channelchek-Plattform verfügbar sein. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung auf allen drei Plattformen zugänglich.
- None.
- None.
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.
A high-definition video webcast of the presentation will be available the following day on the Company's website https://investors.in8bio.com/news-events/events-presentations, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investors and Corporate Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
Patrick McCall, CFO
IN8bio, Inc
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio (INAB) presenting at NobleCon20?
Where can I watch IN8bio's NobleCon20 presentation?
How long will IN8bio's NobleCon20 presentation be available online?
What type of therapies does IN8bio (INAB) develop?
